Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

被引：0
|
作者：
Shuxia Qin
Lidan Yi
Sini Li
Chongqing Tan
Xiaohui Zeng
Liting Wang
Ye Peng
Xiaomin Wan
机构：
[1] Central South University,Department of Pharmacy, The Second Xiangya Hospital
[2] Central South University,Xiangya Nursing School
[3] Central South University,PET
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Atezolizumab; Bladder cancer; Cost-effectiveness; Markov model; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3399 / 3408
页数：9
相关论文
共 50 条
  • [1] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Qin, Shuxia
    Yi, Lidan
    Li, Sini
    Tan, Chongqing
    Zeng, Xiaohui
    Wang, Liting
    Peng, Ye
    Wan, Xiaomin
    ADVANCES IN THERAPY, 2021, 38 (06) : 3399 - 3408
  • [2] Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
    Liu, Xiaoyan
    Lang, Yitian
    Chai, Qingqing
    Lin, Yan
    Liao, Yahui
    Zhu, Yizhun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
  • [4] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024,
  • [5] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [8] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    Advances in Therapy, 2020, 37 : 2116 - 2126
  • [9] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.
    Li, Lingyu
    Wang, Hong
    Li, Wenqian
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li Ling-Yu
    Wang Hong
    Chen Xiao
    Li Wen-Qian
    Cui Jiu-Wei
    中华医学杂志(英文版), 2019, 132 (23) : 2790 - 2794
12345